NEW DELHI -- Biocon Biologics, a subsidiary of Indian biotech giant Biocon, has secured board approval for an investment of $150 million from U.S.-based investment bank Goldman Sachs.
DealStreetAsia
India's Biocon Biologics to receive $150m from Goldman Sachs
Fresh infusion follows Tata's pledge of $30m
Employees of parent Biocon work inside the company's research and development facility in Bangalore, India. © Reuters
Read Next
.jpg?width=700&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=394)
Latest on DealStreetAsia
